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Abstract: The World Health Organization (WHO) defines glycogen-rich clear cell carcinoma (GRCC)
of the breast as a carcinoma with glycogen accumulation in more than 90% of its tumor cells. Due to
the rarity of this disease, its reported survival and clinical associations have been inconsistent due
to reliance on case reports and limited case series. As a result, the prognostic implication of this
cancer subtype remains unclear. Using the U.S. Surveillance, Epidemiology, and End Results (SEER)
program database, we compared the incidence, demographics and prognostic factors of 155 cases of
GRCC of the breast to 1,251,584 cases of other (non-GRCC) breast carcinomas. We demonstrate that
GRCC is more likely to be identified as high grade, advanced stage, and more likely to have triple
negative receptor status. GRCC cases display a poorer prognosis than non-GRCC carcinomas of the
breast irrespective of age, AJCC staging, tumor grade, joint hormone receptor/human epidermal
growth factor receptor 2 (HER2) status, and treatment. Similar to non-GRCC carcinomas, older age
and higher American Joint Committee on Cancer (AJCC)/TNM staging were associated with poorer
prognosis for GRCC, while treatment with surgery and radiation were associated with improved
survival. Radiation, specifically in the setting of breast-conserving surgery, further improved survival
compared to surgery alone. Our study highlights the poorer prognosis associated with glycogen
accumulation in breast cancers and hence stresses the importance of identifying this more aggressive
tumor type.
Keywords: glycogen; breast cancer; SEER program database; clear cell carcinoma; prognosis; survival
1. Introduction
Glycogen is a multibranched, carbohydrate storage molecule made up of monomers of glucose [1,2].
During periods of caloric excess, the level of plasma glucose increases and stimulates glycogen
synthesis in the liver and skeletal muscle. During caloric deficit, glycogen is rapidly degraded to
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glucose to supply energy production via glycolysis and the tricyclic acid (TCA) cycle [2]. Coordinated
regulation of glycogen synthesis and degradation is critical for cellular homeostasis [3]. Microscopic
visualization of glycogen deposits in cells and tissue are important in the diagnosis of diseases with
aberrant glycogen metabolism. Period acid-Schiff (PAS) positive/PAS-diastase (PAS-D) negative
staining is the most commonly used method for histochemical detection of glycogen by pathologists in
multiple diseases [4–6].
Clinicians and pathologists have identified large glycogen granules in multiple cancers, yet the
significance of these deposits remains unknown. These aberrant glycogen accumulations have been
identified in cancers of the breast, kidney, uterus, lung, head and neck, bladder, ovary, and recently,
colorectal tumors [7–14]. Many PAS-positive tumors have earned the term “clear cell” due to the
transparent and ovoid appearance left by the carbohydrate accumulations in the cytoplasm after
fixation and tissue preparation processing. Several theories currently exist with regards to the
mechanism underlying glycogen metabolism changes in cancer cells [15–22]. One popular explanation
is that, under hypoxic conditions in the center of solid tumors, glycogen stores are increased via
hypoxia-inducible factor 1α (HIF1α) mediated signaling pathways to accommodate the low oxygen
levels and nutrient deprivation [13,18,23]. In recent years, cancer research has highlighted multiple
aspects of metabolic re-wiring in malignant cancers with glycogen, at least in part, contributing to
these changes by providing a constant supply of glucose. While multiple pharmacological modulators
of glycogen metabolism are currently being tested, none have yet been clinically approved [22].
Breast cancer is a heterogeneous disease accounting for 30% of all cancers diagnosed in
women [24]. Its routine classification/characterization is based on both histopathology (WHO
recognizes over 20 epithelial subtypes) and immunophenotypic/molecular features such as estrogen
receptor (ER), progesterone receptor (PR) and human epidermal receptor 2 (HER2) status. Intriguingly,
there are several rare histological variants of breast cancer, one of which contains clear cells of
epithelial origin. The optically clear cytoplasm in these cells may be due to various compounds
such as carbohydrate or lipid accumulations; with glycogen as the most commonly identified [25].
Fisher et al. identified glycogen accumulation in 100% of 45 clear cell carcinoma cases [26] and
Hayes et al. reported 21 of 26 clear cell carcinomas were glycogen-rich [27]. Breast carcinoma with
clear cytoplasm containing glycogen (PAS+/PAS-D−) identified in more than 90% of the tumor cells is
classified as glycogen-rich clear cell carcinoma of the breast (GRCC) by the WHO [28].
GRCC is considered an orphan disease as it accounts for less than 3% of all breast carcinomas
cases [26,27,29,30]. There has been an ongoing debate over its prognostic implications. Fisher et al.
identified 45 cases of GRCC among 1555 women with invasive breast cancer [26]. The study noted a
poorer prognosis for GRCC patients, greater frequency of nodal metastasis, and higher histologic grade
(III) when compared to the 1510 cases of non-clear cell carcinomas [26]. However, 24 cases reported by
Ma et al. [31] showed no significant difference in overall survival between GRCC and control invasive
carcinomas when matched by age, tumor size, nodal status, and immune-phenotype. Hayes et al. [27]
reported 21 cases of GRCC and also found that prognosis was not different from non-GRCC when
the tumor was matched by size, grade, and lymph node status. Due to the lack of sufficient cases and
inconsistency in available data, classification of GRCC in terms of prognosis is currently unclear [28,32].
Given the rarity of the cases at any given institution, the Surveillance, Epidemiology, and End Results
(SEER) Program database provides a unique opportunity to perform large population-based studies
on this orphan disease. This study takes advantage of the SEER program database for the retrospective
assessment of incidence, survival, demographics, and prognostic factors for GRCC of the breast.
2. Methods
2.1. Data Source
The Surveillance, Epidemiology and End Results (SEER) Program is the National Cancer Institute’s
authoritative source for cancer incidence and survival [33]. It is considered the gold standard for
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cancer data collection internationally [34]. It is populated with data from national cancer registries,
covering approximately 34.6% of the United States population [33]. Vital status is updated annually
and the database routinely undergoes quality-control checks. The methodology was conducted as
described previously [35].
2.2. Sample Selection and Coding
We queried the SEER database (November, 2017 [36] and November, 2015 submissions, including
data from 1973 to 2015) [36,37] to identify all malignant cancers within the breast (International
Classification of Diseases- (ICD-) O-3 code (ICD-O-3 codes C34.0–C34.3 and C34.8–C34.9), diagnosed
between January 1, 1981 and December 31, 2015. Carcinomas of the breast were determined based
on the adapted classification scheme for adolescents and young adults (AYA). Cases of GRCC were
identified by ICD-O-3 codes 8310 (clear cell carcinoma (CC)) and 8315 (glycogen-rich carcinoma (GR)).
According to the WHO Classifications of Tumors, in the case of breast carcinomas, ICD-O-3 codes
8310 (CC) and 8315 (GR) are considered equivalent and both refer to GRCC [28]. Therefore, the two
histological groups, CC and GR, were combined in our analysis and henceforth referred to as GRCC.
Follow-up subgroup analysis of CC and GR cases were also conducted separately.
The following variables were collected and coded: AYA site recode, primary site, ICD-O-3 histology,
age at diagnosis, sex, race, grade, ER status, PR status, HER2 status, immunohistochemistry (IHC)
based intrinsic subtype of breast cancer, American Joint Commission on Cancer (AJCC) 6th Edition
Staging, AJCC 6th Edition tumor size (T), lymph nodes affected (N), and metastasis (M) Staging, bone
metastasis at diagnosis, brain metastasis at diagnosis, liver metastasis at diagnosis, lung metastasis
at diagnosis, surgery at primary site, and radiation. Details of coding for hormone receptor and
HER2 status are available on the SEER website (https://seer.cancer.gov/seerstat/databases/ssf/her2-
derived.html) and in the AJCC Collaborative Stage Data Collection System Coding Manual [38]. Cases
diagnosed at autopsy or that could have 0 days of follow-up were excluded.
2.3. Statistical Analysis
All statistical analyses was carried out using the IBM SPSS Statistics software package (version 25,
International Business Machines Corporation, Armonk, NY, USA). Differences in demographic and
clinical characteristics between GRCC and non-GRCC cases were determined using the Pearson’s
chi-square test and column proportions were compared using Bonferroni correction to adjust for
multiple comparisons. Median survival times were determined using the Kaplan-Meier method
and the significance of the difference was determined using the log-rank test. Multivariable
analyses of overall survival were conducted using the Cox Proportional Hazards Ratios (HR) model.
Corresponding hazard ratios and 95% confidence intervals (CI) were estimated from the model.
Two-tailed p-values <0.05 were considered statistically significant.
3. Results
3.1. Demographics and Clinical Characteristics
Our SEER Program query identified 1,256,901 cases of malignant breast carcinoma. From these
cases of interest, cases diagnosed at autopsy or that could have 0 days of follow-up (n = 5162, 0.4%)
were excluded. The final number of cases included in our analysis was 1,251,739. Out of these,
110 cases (0.008%) were identified as CC and 45 of the cases (0.003%) were classified as GR. According
to the WHO, the two terms are synonymous when referring to breast carcinomas [28] and since
each patient could only be classified by one ICD code, both CC and GR cases were combined and
henceforth referred to as GRCC. We first described our findings in the GRCC combined population.
We then conducted subgroup analyses on GR and CC carcinomas, separately comparing these cases to
non-GRCC cases and to each other; those results will be described subsequently.
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Among all carcinomas of the breast, the median follow-up time was 60 months (range: 0 to
395 months), with 414,019 recorded deaths. In the GRCC population, the median follow-up time was
54 months (range: 2 to 96 months), with 63 deaths. The demographical and clinical characteristics of the
patient population are summarized in Table 1. The median age at diagnosis of GRCC of the breast was
62 years old compared to 60 years old in non-GRCC carcinomas of the breast (p = 0.46). The majority of
patients with GRCC carcinoma were female (98.1%) and ethnically white (80.6%), and 92.9% of GRCC
patients received surgery and 45.7% received radiation therapy. We found that grade (p < 0.001), ER
status (p < 0.001), PR status (p < 0.001), IHC based intrinsic subtypes (p < 0.001), AJCC 6th staging
(p = 0.03), T status (p = 0.01) and brain metastasis (p = 0.03) significantly differed between GRCC
and non-GRCC carcinomas of the breast; although only a single case of GRCC with brain metastasis
was available in our analysis. GRCC were statistically more likely to be Grade III (GRCC: 41.3% vs.
non-GRCC carcinomas: 29.2%) and grade IV (GRCC: 3.2% vs. non-GRCC carcinomas: 1.4%), ER
negative (GRCC: 40.3% vs. non-GRCC carcinomas: 17.9%), PR negative (GRCC: 58.3% vs. non-GRCC
carcinomas: 27.4%), triple negative (GRCC: 44.8% vs. non-GRCC carcinomas: 10.4%), T2 status (GRCC:
36.8% vs. non-GRCC carcinomas: 23.6%), and positive for brain metastasis at diagnosis (GRCC: 3.4%
vs. non-GRCC carcinomas: 0.4%).
Table 1. Demographical and clinical characteristics.
GRCC Non-GRCC
Count % Count % p-Value
Age 0–60 years 78 50.3% 592,544 47.3% 0.46>60 years 77 49.7% 659,040 52.7%
Sex
Female 152 98.1% 1,242,647 99.3%
0.07Male 3 1.9% 8937 0.7%
Race
American Indian/Alaska Native 1 0.6% 6099 0.5%
0.98
Asian or Pacific Islander 12 7.7% 85,407 6.8%
Black 16 10.3% 123,081 9.8%
Unknown 1 0.6% 5967 0.5%
White 125 80.6% 1,031,030 82.4%
Grade
Well differentiated; Grade I 5 3.2% 216,525 17.3%
<0.001
Moderately differentiated; Grade II 53 34.2% 446,827 35.7%
Poorly differentiated; Grade III 64 * 41.3% 365,903 29.2%
Anaplastic; Grade IV 5 * 3.2% 16,937 1.4%
Unknown 28 18.1% 205,392 16.4%
ER Status a
Negative 58 * 40.3% 203,173 17.9%
<0.001
Positive 67 46.5% 807,640 * 71.1%
Borderline 0 0.0% 2837 0.2%
Unknown 19 13.2% 121,600 10.7%
PR Status a
Negative 84 * 58.3% 310,973 27.4%
<0.001
Positive 40 27.8% 683,610 * 60.2%
Borderline 0 0.0% 5794 0.5%
Unknown 20 13.9% 134,873 11.9%
HER2 Status c
Negative 25 86.2% 291,238 78.5%
0.56
Positive 2 6.9% 52,021 14.0%
Borderline 0 0.0% 8250 2.2%
Unknown 2 6.9% 19,359 5.2%
IHC based intrinsic
Subtypes c
HER2−/HR+ 12 41.4% 251,946 * 67.9%
<0.001
HER2+/HR− 1 3.4% 15,597 4.2%
HER2+/HR+ 1 3.4% 36,269 9.8%
Triple Negative 13 * 44.8% 38,750 10.4%
Unknown 2 6.9% 28,306 7.6%
AJCC 6th Stage
I 54 34.8% 525,652 42.0%
0.03
II 59 * 38.1% 365,536 29.2%
III 17 11.0% 139,296 11.1%
IV 11 7.1% 54,270 4.3%
Unknown 14 9.0% 166,830 13.3%
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Table 1. Cont.
GRCC Non-GRCC
Count % Count % p-Value
T
T0 0 0.0% 1110 0.1%
0.01
T1 63 40.6% 647,840 * 51.8%
T2 57 * 36.8% 295,198 23.6%
T3 7 4.5% 49,233 3.9%
T4 3 1.9% 33,931 2.7%
Tis 0 0.0% 1791 0.1%
Unknown 25 16.1% 222,481 17.8%
N
N0 91 58.7% 718,198 57.4%
0.79
N1 32 20.6% 234,449 18.7%
N2 9 5.8% 68,563 5.5%
N3 6 3.9% 48,862 3.9%
Unknown 17 11.0% 181,512 14.5%
M
M0 132 85.2% 1,083,182 86.5%
0.21M1 11 7.1% 54,270 4.3%
Unknown 12 7.7% 114,132 9.1%
Bone Metastasis c
No Metastasis 27 93.1% 351,795 94.9%
0.72Metastasis 1 3.4% 13,264 3.6%
Unknown 1 3.4% 5809 1.6%
Brain Metastasis c
No Metastasis 27 93.1% 363,212 97.9%
0.03Metastasis 1 * 3.4% 1501 0.4%
Unknown 1 3.4% 6155 1.7%
Liver Metastasis c
No Metastasis 27 93.1% 359,794 97.0%
0.46Metastasis 1 3.4% 5079 1.4%
Unknown 1 3.4% 5995 1.6%
Lung Metastasis c
No Metastasis 27 93.1% 358,514 96.7%
0.56Metastasis 1 3.4% 6,198 1.7%
Unknown 1 3.4% 6,156 1.7%
Surgery b
No Surgery 7 5.5% 70,372 7.3%
0.38Surgery 118 92.9% 889,255 92.0%
Unknown 2 1.6% 6822 0.7%
Extent of Surgery b
No Surgery 8 6.3% 75,877 7.9%
0.51
Sub-Mastectomy # 70 55.1% 485,610 50.2%
Mastectomy 48 37.8% 401,380 41.5%
Surgery, Unknown 0 0.0% 1358 0.1%
Unknown 1 0.8% 2224 0.2%
Radiation b
No Radiation 64 50.4% 426,196 44.1%
0.21Radiation 58 45.7% 513,445 53.1%
Unknown 5 3.9% 26,808 2.8%
Bolded are statistically significant p-values when comparing between clear cell/glycogen rich to other carcinomas
of the breast. * Statistically significant differences between column proportions. # Defined as any surgery less
aggressive than total mastectomy. a,b,c Variable available for cases diagnosed after 1990, 1998 and 2010 respectively.
GRCC—glycogen-rich clear cell; ER—estrogen receptor; PR—progesterone receptor; IHC—immunohistochemistry;
HER2—human epidermal growth factor receptor 2; HER2+—human epidermal growth factor receptor 2 positive;
HER2−—human epidermal growth factor receptor 2 negative; HR+—hormone receptor positive; HR−—hormone
receptor negative; AJCC—American Joint Committee on Cancer; T, N, M refers to tumor size, nodal status, and
metastasis classifications of malignant tumor staging system, respectively.
3.2. Survival
The median survival time for GRCC patients was 158 months vs. 176 months for non-GRCC breast
carcinomas (p = 0.02, Figure 1). The corresponding 5-, 10- and 15-year survival rates for GRCC were
70%, 53%, and 44%, respectively, whereas the 5-, 10-, 15-year survival rate for non-GRCC carcinomas
was 79%, 64%, and 51%. After adjusting for age, disease stage, tumor grade, ER status, PR status,
HER2 status, surgery status, and radiation treatment, survival for GRCC remained significantly poorer
compared to non-GRCC carcinomas (HR: 1.33; 95% CI: 1.04–1.67; p = 0.025).
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Figure 1. Kaplan- eier curves for overall survival based on histological subtype.
Among GRCC patients, older age (p = 0.002), higher AJCC stage (p < 0.001), T status (p < 0.001),
N status (p = 0.001), and M status (p < 0.001) were also associated with significantly poorer survival
(Table 2, Figure 2A), whereas surgery (p < 0.001) and radiation treatments (p = 0.02) significantly
improved survival (Figure 2B left two panels). We further assessed the combination of surgery and
radiation treatment on patient survival (Figure 2B, right two panels). We identified a significant
survival improvement in patients who underwent sub-mastectomy—defined as any surgery less
than a total mastectomy, plus radiation treatment compared to individuals who only underwent
sub-mastectomy (p = 0.02). However, when total mastectomy was combined with radiation treatment,
no improvement in survival was observed (p = 0.89). We found that age (HR: 1.05; 95% CI: 1.02–1.07;
p < 0.001); AJCC stage III (HR: 4.67; 95% CI: 1.84–11.87; p = 0.001); AJCC stage IV (HR: 15.84; 95%
CI: 4.11–60.97; p < 0.001); and radiation (HR: 0.47; 95% CI: 0.25–0.90; p = 0.02) remained significant
prognostic factors for survival in our subsequent multivariable analysis after accounting for age, AJCC
stage, surgery, or radiation (Table 3).
Table 2. Survival durations for glycogen-rich clear cell (GRCC) carcinoma patients.
Median (Months)
95% CI
p-Value
Lower Up er
All GRCC cases 158 96.5 219.5 NA
Age 60 years and under 158 96.6 219.4 0.002>60 year 73 18.6 127.4
Sex
Female - - -
0.56Male 81 62.5 99.5
Race
American Indian/Alaska N tiv 27 - -
0.16
Asian or Pacific Islander - - -
Black - - -
White 111 45.6 176.4
Grade
Well t Moderately Differentiated 162 105.1 218.9
0.19Poorly Differentiated to
Anaplastic 111 - -
ER Status
Negative 158 69.3 246.7
0.82Positive 174 61.2 286.8
PR Status
Negative 158 86.3 229.7
0.15Positive - - -
AJCC Stage
I 162 125.7 198.3
<0.001
II - - -
III 69 38.4 99.6
IV 30 7.9 52.1
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Table 2. Cont.
Median (Months)
95% CI
p-Value
Lower Upper
T
T1 158 125.4 190.6
0.005
T2 - - -
T3 27 - -
T4 25 - -
N
N0 174 - -
0.001
N1 81 15.3 146.7
N2 69 - -
N3 50 12.3 87.7
M
M0 162 121.1 202.9
<0.001M1 30 7.9 52.1
Surgery No Surgery 25 0.0 58.1 <0.001Surgery 158 100.4 215.6
Extent of
Surgery
No Surgery 25 0.0 58.1
0.02Sub-Mastectomy # 174 116.0 232.0
Mastectomy 108 - -
Radiation
No Radiation 81 40.4 121.6
0.012Radiation - - -
HER2 Status was only available for cases diagnosed after 2010 and was therefore excluded from the analysis.
Bolded are statistically significant p-values. “-” Median survival time not reached or could not be calculated.
# Defined as any surgery less aggressive than total mastectomy. CI—confidence interval; ER—estrogen receptor;
PR—progesterone receptor; AJCC—American Joint Committee on Cancer; NA—not applicable; T, N, M refers to
tumor size, nodal status, and metastasis classifications of malignant tumor staging system, respectively.
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Figure 2. Kaplan- eier curves for glycogen-rich clear cell (GRCC) based on (A) clinical factors and
(B) treatment. AJCC American Joint Committee on Cancer; T, N, refers to tumor size, nodal status,
and metastasis classifications of malignant tumor staging system, respectively; RT—radiation therapy.
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Table 3. Multivariable analysis of overall survival for glycogen-rich clear cell (GRCC.) patients.
Variable Reference p-Value HR
95% CI
Lower Upper
Age <0.001 1.05 1.02 1.07
AJCC Stage
I <0.001
II 0.64 1.18 0.60 2.34
III 0.001 4.67 1.84 11.87
IV <0.001 15.84 4.11 60.97
Surgery No Surgery 0.39 2.05 0.40 10.45
Radiation No Radiation 0.02 0.47 0.25 0.90
Bolded are statistically significant p-values. CI—confidence interval; HR—hazards ratio; AJCC—American Joint
Committee on Cancer.
3.3. Subgroup Analysis of GR and CC Carcinoma of the Breast
To confirm our finding in the combined GRCC cases, we also conducted subgroup analyses on
the GR and CC cases, comparing them to non-GRCC separately. The 45 cases of GR carcinoma had
a median age at diagnosis of 61 years. The demographical and clinical characteristics of this patient
subpopulation showed similar trends to those previously described in GRCC carcinomas of the breast
(Supplemental Table S1). We found that grade (p = 0.04), ER status (p = 0.02), PR status (p = 0.003),
receptor subtype (p = 0.002), T status (p = 0.02) and brain metastasis (p < 0.001) remained significantly
differed between GR and non-GRCC carcinomas of the breast. AJCC 6th staging had a borderline
significance (p = 0.06). The median survival time for GR was 133 months, with 5-, 10- and 15-year
survival rates of 75%, 56%, and 45%, respectively. However, these survival durations no longer differed
significantly from non-GRCC patients (p = 0.50, Supplemental Figure S1a). When comparing survival
based on various demographic/clinical factors for the GR subgroup, only N staging reached statistical
significance (p < 0.02, Supplemental Table S2). AJCC stage (p = 0.12), T status (p = 0.06), surgery
(p = 0.06), and radiation (p = 0.10), factors which were identified as prognostic factors in our analysis
of GRCC carcinomas, showed a consistent trend towards an effect on survival in the GR subgroup
(Supplemental Table S2). Radiation after sub-mastectomy, however, remained significant in improving
survival in GR patients (p = 0.04, Supplemental Figure S1b).
The 110 CC cases also displayed similar trends in demographical and clinical characteristics as
the GRCC combined group (Supplemental Table S3). The only exceptions were that CC patients were
more likely to be male than non-GRCC carcinoma patients of the breast (2.7% vs. 0.7%, p =0.012)
and that they were no longer significantly different from non-GRCC patients with regards to brain
metastasis at diagnosis (p = 0.31). Among CC cases, 5-, 10, and 15- year survival rates were 75%, 56%,
and 45%, respectively. Median survival duration was 158 months, which was significantly worse than
non-GRCC carcinomas of the breast (176 months in other carcinomas, p = 0.02, Supplemental Figure S2).
CC patients displayed poorer survival compared to non-GRCC patients after accounting for age, stage,
tumor grade, ER/PR/HER2 status, surgery and radiation (HR: 1.33; 95% CI: 1.00–1.76; p = 0.047).
Prognostic factors for CC cases included age (p = 0.006), AJCC stage (p < 0.001), T status (p = 0.04),
N status (p = 0.02), M status (p < 0.001), surgery (p < 0.001) and radiation (p = 0.05) (Supplemental
Table S4). Age (p < 0.001) and stage (p < 0.001) remained independent prognostic factors of poorer
survival in multivariable analysis (Supplemental Table S5).
When comparing CC directly to the GR subgroup, there were no significant differences in
demographical and clinical characteristics (Supplemental Table S6) or survival durations (p = 0.59,
Supplemental Figure S3).
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4. Discussion
Using the SEER Program database, our study identified that GRCC is an aggressive histology
with a poorer prognosis than non-GRCC carcinomas of the breast. Most importantly, the poorer
prognosis was irrespective of the AJCC stage, tumor grade, patient age, treatment, and molecular
subtypes defined by ER/PR/HER2 status. Our findings of poorer prognosis in GRCC carcinomas of
the breast mirrors the poorer outcomes of clear cell carcinomas of other origins, such as the kidney [39],
uterus [40], and ovaries [41]. We further identified that prognostic factors for non-GRCC breast
carcinomas, such as age and AJCC staging, including TNM staging, were also relevant for GRCC
tumors. Moreover, treatment with radiation and surgery showed improvements in survival for GRCC
cases. Specifically, radiation was associated with improved survival when less aggressive surgical
procedures (i.e., breast-conserving surgeries) were performed. This finding is consistent with the
standard of care for other breast carcinomas [42] and suggests that GRCC may be treated similarly.
While similar trends were observed in the GR subgroup, statistical significance was not reached, likely
due to the smaller number of cases as compared to the GRCC analysis. In the CC cases, the significance
of two demographic/clinical factors differed from our GRCC analysis possibly due to variations in the
selected cases.
Several biomolecular theories have been investigated as the reasoning for poorer prognosis
of GRCC tumors. Aberrant glycogen can act as an additional fuel source in nutrient-deprived
tumor microenvironments. Tumor cells have been shown to have the ability to mobilize glycogen to
fuel glycolysis and cellular proliferation via a p38α mitogen-activated protein kinase (p38α-MAPK)
signaling pathway [43]. Hypoxia-induced glycogen phosphorolysis (the breakdown of glycogen into
glucose) has also been found to enhance tumorigenesis by suppressing reactive oxygen species levels
and p53-dependent senescence [13]. Furthermore, glycogen accumulation in tumor-associated stroma
was identified recently to play key roles in tumor microenvironment by supplying carbohydrate for
tumor proliferation [43]. Although further investigations are needed, elevated levels of glycogen
content in breast cancer may participate in similar signaling pathways to potentiate tumor growth.
Triple-negative breast tumors account for 15–20% of all breast cancers and their highly aggressive
nature is well documented [44,45]. These tumors have poorer prognosis due to both the lack of
receptors available for targeted therapies and they also have higher metabolic demands for cell
division. Basu et al. demonstrated significantly higher fluorine-18 fluorodeoxyglucose (FDG) uptake
in triple negative tumors compared with uptake in ER+/PR+/HER2− tumors using FDG-positron
emission tomography [46]. Studies have also demonstrated a greater glycolytic phenotype and altered
mitochondrial respiration in triple negative patient tumors and cell lines compared with other tumor
subtypes [47–49]. These data are suggestive of a more metabolically active phenotype, likely to
compensate for increased cellular proliferation rates. High glycogen content could be utilized to satisfy
these demands when the solid tumor grows beyond the limit of nutrient diffusion. Although our
multivariable analysis showed that the poorer prognosis of GRCC was irrespective of IHC intrinsic
receptor subtype, the increased metabolic needs of triple negative tumors suggest that it may still be a
factor in influencing the poorer prognosis of GRCC. However, only 29 cases were available for analysis
as HER2 receptor status was only available after 2010 in the SEER database. Therefore the relationship
between glycogen and triple negative tumors requires further examination.
The most widely accepted technique for glycogen histochemistry is PAS staining [50]. However,
PAS not only detects glycogen; it also stains other polysaccharides such as glycoprotein, proteoglycans,
and mucins [51–53]. Another disadvantage of PAS is the lack of sensitivity; only large polysaccharide
inclusions can be identified by PAS. Given that our database analysis identified only a small number
of GR (45 cases) compared to CC (110 cases), we speculate that glycogen accumulations may be
under-identified due to the lack of PAS sensitivity. Routine glycogen staining may also be underutilized
as clinicians do not feel the need to additionally assess the specific intracytoplasmic moiety as no
specific treatment guidelines currently exist for GRCC. However, the poorer prognostic outcome
for GRCC tumors illustrated in our study highlights the utility of accurate subtyping of invasive
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carcinomas in order to improve our understanding of the prognostic variables. Detailed histological
characterization will also provide clinicians with an opportunity for detailed assessment of treatment
outcomes depending on the subtype of the disease. Given the importance of glycogen in patient
survival and cancer prognosis, more specific and accurate methods for glycogen detection may
be warranted.
While less common than glycogen accumulations, various histological subtypes of CC carcinoma
without glycogen can exist. Apocrine, lipid-rich, pleomorphic lobular (histiocytoid) or secretory
carcinomas all can have a histologically “clear cell” appearance [27,32]. Consistent with previous
studies, the lack of differentiation between the CC and GR cases in our subgroup analysis provides
further evidence that the majority of CC cases are expected to be GR. As we were unable to confirm the
presence of glycogen accumulation in the CC carcinomas of our retrospective database analysis, larger
studies of CC carcinomas with validated GR cases are needed to confirm the clinical and prognostic
factors identified in our study. Due to the rarity of GRCC cases, only a single positive case was
available for our analysis of bone, brain, liver and lung metastasis at the time of diagnosis. Although
GRCC reached a statistically higher chance of brain metastasis when compared to non-GRCC, future
studies with a larger number of positive cases are needed to confirm these results. Furthermore,
chemotherapy information was not available in the SEER program database. A follow-up study that
includes chemotherapy treatment would further our understanding of the disease and establish better
treatment options.
5. Conclusions
While it has previously been difficult to accurately assess clinical characteristics and prognosis
of GRCC due to the rarity of their presentation, using the SEER program database we were able to
examine 155 of these cases. Our results demonstrated that GRCC is an aggressive histology with a
poorer prognosis irrespective of AJCC stage, tumor grade, patient age, treatment, and ER/PR/HER2
status. To further clarify the characteristics and prognosis of GRCC of the breast, a large, systematic
study of histologically confirmed glycogen-rich cases with long-term follow up will be necessary. As it
has not been possible to study these rare tumors in randomized clinical trials to determine optimal
surgical, radiation or chemotherapeutic strategies, more sensitive histological characterization methods
may be warranted in order to further identify prognostic variables and to promote the development of
targeted therapies for these patients.
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